AstraZeneca and its global biologics research and development arm MedImmune are set to report results of more than 40 clinical trial presentations at the European Society of Medical Oncology (ESMO) 2017 Congress to be held in Madrid, Spain, from 8-12 September.
The firms intend to highlight results from Phase III PACIFIC and FLAURA trials conducted for the treatment of non-small-cell lung cancer (NSCLC).
During the PACIFIC trial, Imfinzi (durvalumab) is reported to have demonstrated statistically significant and clinically meaningful progression-free survival (PFS) in locally advanced (stage III) unresectable NSCLC patients after standard chemoradiation therapy.
Tagrisso (osimertinib) is said to have shown similar action in the FLAURA trial when compared to erlotinib or gefitinib as first-line treatments in previously untreated, locally advanced or metastatic NSCLC patients positive for epidermal growth factor receptor mutation (EGFRm).
Additionally, Tagrisso’s overall survival data from Phase II AURA trials performed in EGFR T790M mutation-positive advanced NSCLC patients, and PFS results and central nervous system (CNS) responses of EGFR T790M NSCLC patients to the drug in the Asia Pacific region will be presented.
AstraZeneca oncology business unit executive vice-president and head Jamie Freedman said: “The superiority of first-line treatment with Tagrisso in the FLAURA trial and the potentially transformative Imfinzi data from the PACIFIC trial reinforce our significant contribution to advancing medicines for patients across multiple stages of lung cancer.”
Furthermore, the firms will report data on Lynparza for the treatment of HER2-negative metastatic breast cancer in Phase III OlympiAD trial and for platinum-sensitive relapsed ovarian cancer in SOLO-2 trial.
Additional results from Phase II HAWK and Phase Ib/II SCORES trials supporting the efficacy and safety of Imfinzi to treat head and neck squamous cell carcinoma will also be highlighted.
Image: AstraZeneca R&D facility in Sweden. Photo: courtesy of AstraZeneca.